Literature-reported formulation composition
Component: DODMA | mol%: 50 | Role: Ionizable lipid
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Component: DODMA | mol%: 50 | Role: Ionizable lipid
Component: Cholesterol | mol%: 39 | Role: Sterol
Component: DOPE | mol%: 11 | Role: Helper phospholipid
Component: Reported total | mol%: 100 | Role: Source values retained
Measurement: Diameter (nm) | Initial core: 146 ± 1 | Three-layer HA-LNP: 177 ± 2
Measurement: PDI | Initial core: 0.27 ± 0.01 | Three-layer HA-LNP: 0.18 ± 0.02
Measurement: RNA assay (%) | Initial core: 90 ± 1 (core EE) | Three-layer HA-LNP: 88 ± 1 (layer RNA; indirect)
Literature-reported Three-layer particle diameter 177 ± 2 nm Mean ± SD; DLS Z-average Main Results 3.1; Fig.1
Literature-reported Three-layer PDI 0.18 ± 0.02 Mean ± SD; DLS Main Results 3.1; Fig.1
Literature-reported Core siRNA encapsulation 90 ± 1% SYBR Gold; disrupted versus intact cores Main Results 3.1; Fig.1
Literature-reported Layer-associated siRNA (indirect) 88 ± 1% Indirect SYBR Gold accessibility estimate; not a direct recovery assay Main Results 3.1; Fig.1
Literature-reported Residual luciferase activity 44 ± 2% of untreated cells Three-layer HA-LNP; siLuc 180 nM; GL261-Luc cells · 48 h · Untreated cells; scrambled-siRNA particle control Main Results 3.1; Fig.1
Coating composition is additional to the lipid core The 50/39/11 mol% table covers lipid core components only. To obtain the measured three-layer particles, 7 microlitres of 20 micromolar siRNA, 1 microlitre of 2 mg/mL poly-L-arginine and 5 microlitres of 5 mg/mL hyaluronic acid were added sequentially to 14.1 microlitres core suspension. Ten minutes at room temperature after each layer · Methods 2.2
In vitro tolerability scope No significant loss of cell viability was reported for the three-layer particles at 180 nM siRNA in the 48 h GL261-Luc assay. This is not systemic or long-term safety evidence. WST-8 viability alongside luciferase assay · Methods 2.5; Results 3.1; Fig.1D